| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anemia, Aplastic | 17 | 2014 | 226 | 2.820 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 49 | 2022 | 5442 | 2.480 |
Why?
|
| Isoantigens | 8 | 2019 | 567 | 2.030 |
Why?
|
| Bone Marrow Transplantation | 31 | 2015 | 2765 | 1.690 |
Why?
|
| Clonal Anergy | 7 | 2014 | 169 | 1.620 |
Why?
|
| Leukocytes, Mononuclear | 9 | 2021 | 1836 | 1.210 |
Why?
|
| Hepatic Veno-Occlusive Disease | 7 | 2016 | 220 | 1.140 |
Why?
|
| T-Lymphocytes, Regulatory | 7 | 2023 | 2988 | 1.060 |
Why?
|
| Immunosuppressive Agents | 11 | 2023 | 4149 | 1.040 |
Why?
|
| Fanconi Anemia | 10 | 2018 | 319 | 0.890 |
Why?
|
| Tacrolimus | 3 | 2023 | 743 | 0.880 |
Why?
|
| Polydeoxyribonucleotides | 4 | 2016 | 127 | 0.810 |
Why?
|
| Transplantation Conditioning | 12 | 2019 | 1598 | 0.800 |
Why?
|
| Transplantation, Homologous | 22 | 2022 | 4776 | 0.780 |
Why?
|
| Lymphocyte Culture Test, Mixed | 3 | 2019 | 517 | 0.750 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 7 | 2001 | 903 | 0.660 |
Why?
|
| Bone Marrow Diseases | 4 | 2013 | 231 | 0.660 |
Why?
|
| Immune Tolerance | 3 | 2019 | 2258 | 0.650 |
Why?
|
| T-Lymphocytes | 15 | 2018 | 10180 | 0.640 |
Why?
|
| Graft vs Host Disease | 25 | 2018 | 2957 | 0.620 |
Why?
|
| Myelodysplastic Syndromes | 9 | 2018 | 1352 | 0.590 |
Why?
|
| Transaminases | 2 | 2006 | 199 | 0.520 |
Why?
|
| Transplantation Tolerance | 2 | 2021 | 617 | 0.520 |
Why?
|
| Multiple Organ Failure | 5 | 2016 | 390 | 0.510 |
Why?
|
| Blood Proteins | 3 | 2011 | 1124 | 0.500 |
Why?
|
| Transplantation Immunology | 3 | 2012 | 546 | 0.500 |
Why?
|
| Antimicrobial Cationic Peptides | 3 | 2011 | 362 | 0.470 |
Why?
|
| Endotoxins | 2 | 2013 | 527 | 0.470 |
Why?
|
| Bone Marrow | 10 | 2019 | 2948 | 0.470 |
Why?
|
| Lymphocyte Activation | 7 | 2019 | 5524 | 0.460 |
Why?
|
| Lymphocyte Transfusion | 2 | 2018 | 236 | 0.440 |
Why?
|
| Immunoconjugates | 4 | 2012 | 901 | 0.440 |
Why?
|
| Liver Transplantation | 3 | 2021 | 2119 | 0.440 |
Why?
|
| Fibrinolytic Agents | 4 | 2016 | 2158 | 0.430 |
Why?
|
| Leukemia | 7 | 2018 | 1511 | 0.430 |
Why?
|
| Mouth Mucosa | 3 | 2016 | 434 | 0.420 |
Why?
|
| Hair Color | 1 | 2013 | 136 | 0.420 |
Why?
|
| Lymphocytes | 3 | 2018 | 2617 | 0.410 |
Why?
|
| Child, Preschool | 55 | 2017 | 41006 | 0.410 |
Why?
|
| Interleukin-3 | 4 | 2018 | 444 | 0.390 |
Why?
|
| Stem Cell Transplantation | 3 | 2004 | 1620 | 0.390 |
Why?
|
| Hematologic Neoplasms | 8 | 2019 | 1832 | 0.370 |
Why?
|
| Fluoroquinolones | 1 | 2011 | 310 | 0.350 |
Why?
|
| Child | 64 | 2022 | 77709 | 0.330 |
Why?
|
| Bone Marrow Cells | 7 | 2005 | 2513 | 0.330 |
Why?
|
| Mucositis | 3 | 2018 | 101 | 0.330 |
Why?
|
| Parenteral Nutrition | 5 | 2012 | 650 | 0.320 |
Why?
|
| Endotoxemia | 3 | 2011 | 207 | 0.320 |
Why?
|
| Acute-Phase Proteins | 2 | 2013 | 262 | 0.320 |
Why?
|
| CD4-Positive T-Lymphocytes | 4 | 2018 | 4386 | 0.320 |
Why?
|
| Awards and Prizes | 1 | 2013 | 375 | 0.320 |
Why?
|
| Adolescent | 64 | 2022 | 85781 | 0.310 |
Why?
|
| Cord Blood Stem Cell Transplantation | 4 | 2016 | 314 | 0.300 |
Why?
|
| Whole-Body Irradiation | 5 | 2019 | 449 | 0.300 |
Why?
|
| Nitrogen Oxides | 2 | 2018 | 129 | 0.290 |
Why?
|
| Myeloablative Agonists | 2 | 2018 | 218 | 0.290 |
Why?
|
| Humans | 129 | 2023 | 744343 | 0.280 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 5 | 2013 | 1519 | 0.280 |
Why?
|
| Antigen-Presenting Cells | 3 | 2019 | 973 | 0.270 |
Why?
|
| Exercise | 4 | 2017 | 5615 | 0.270 |
Why?
|
| Artificial Intelligence | 1 | 2019 | 2214 | 0.270 |
Why?
|
| Infant | 30 | 2019 | 35136 | 0.270 |
Why?
|
| Herpesvirus 3, Human | 2 | 2006 | 204 | 0.260 |
Why?
|
| Neoplasms | 13 | 2022 | 21683 | 0.260 |
Why?
|
| Kidney Transplantation | 2 | 2020 | 4251 | 0.250 |
Why?
|
| Energy Metabolism | 5 | 2012 | 2899 | 0.240 |
Why?
|
| Radiation Injuries | 2 | 2011 | 1180 | 0.240 |
Why?
|
| Parents | 5 | 2017 | 3407 | 0.240 |
Why?
|
| Herpes Zoster | 2 | 2006 | 264 | 0.240 |
Why?
|
| Haemophilus Vaccines | 5 | 1998 | 69 | 0.240 |
Why?
|
| Kidney Failure, Chronic | 2 | 2016 | 2538 | 0.230 |
Why?
|
| Blood Transfusion, Intrauterine | 1 | 2003 | 26 | 0.230 |
Why?
|
| Graft Rejection | 4 | 2023 | 4397 | 0.230 |
Why?
|
| alpha-Thalassemia | 1 | 2003 | 46 | 0.230 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 2009 | 648 | 0.220 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2004 | 236 | 0.220 |
Why?
|
| Mouth Diseases | 1 | 2005 | 241 | 0.220 |
Why?
|
| Severe Combined Immunodeficiency | 1 | 2005 | 223 | 0.220 |
Why?
|
| Cyclophosphamide | 8 | 2019 | 2242 | 0.220 |
Why?
|
| Male | 72 | 2019 | 350118 | 0.220 |
Why?
|
| Histocompatibility Testing | 5 | 2008 | 741 | 0.220 |
Why?
|
| Survival Rate | 12 | 2019 | 12788 | 0.220 |
Why?
|
| Defensins | 1 | 2002 | 35 | 0.220 |
Why?
|
| Blood Transfusion | 6 | 2015 | 1301 | 0.210 |
Why?
|
| Tissue Donors | 6 | 2018 | 2240 | 0.210 |
Why?
|
| Lymphoproliferative Disorders | 2 | 2005 | 523 | 0.210 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2014 | 4479 | 0.210 |
Why?
|
| HLA Antigens | 5 | 2012 | 1381 | 0.210 |
Why?
|
| Adult | 56 | 2022 | 214055 | 0.210 |
Why?
|
| Antilymphocyte Serum | 4 | 2017 | 492 | 0.200 |
Why?
|
| Hematologic Diseases | 1 | 2006 | 498 | 0.200 |
Why?
|
| Mycophenolic Acid | 1 | 2023 | 343 | 0.190 |
Why?
|
| Influenza A virus | 1 | 2004 | 456 | 0.190 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2002 | 272 | 0.190 |
Why?
|
| Radiation-Protective Agents | 2 | 2018 | 90 | 0.190 |
Why?
|
| Fanconi Anemia Complementation Group D2 Protein | 2 | 2018 | 148 | 0.190 |
Why?
|
| Dyskeratosis Congenita | 2 | 2015 | 72 | 0.190 |
Why?
|
| Allied Health Personnel | 1 | 2022 | 162 | 0.190 |
Why?
|
| Computational Biology | 1 | 2013 | 3521 | 0.190 |
Why?
|
| Neuroblastoma | 3 | 2006 | 1226 | 0.180 |
Why?
|
| Female | 65 | 2019 | 380194 | 0.180 |
Why?
|
| Antigens, Differentiation | 5 | 1999 | 927 | 0.180 |
Why?
|
| Steroids | 2 | 2023 | 930 | 0.180 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2001 | 227 | 0.180 |
Why?
|
| Membrane Glycoproteins | 3 | 2013 | 3768 | 0.180 |
Why?
|
| Rest | 3 | 2012 | 901 | 0.180 |
Why?
|
| Busulfan | 2 | 2017 | 263 | 0.170 |
Why?
|
| Thinness | 1 | 2022 | 480 | 0.170 |
Why?
|
| Living Donors | 1 | 2023 | 620 | 0.170 |
Why?
|
| Parent-Child Relations | 2 | 2014 | 747 | 0.160 |
Why?
|
| Homozygote | 1 | 2003 | 1785 | 0.160 |
Why?
|
| Nutritional Requirements | 2 | 2011 | 286 | 0.160 |
Why?
|
| Antiemetics | 1 | 2000 | 177 | 0.160 |
Why?
|
| Carrier Proteins | 3 | 2013 | 5021 | 0.160 |
Why?
|
| Flow Cytometry | 5 | 2014 | 5974 | 0.160 |
Why?
|
| Thrombocytopenia | 2 | 1998 | 1179 | 0.160 |
Why?
|
| Histocompatibility | 1 | 1999 | 330 | 0.160 |
Why?
|
| Physical Therapy Modalities | 1 | 2022 | 550 | 0.160 |
Why?
|
| Radiation Injuries, Experimental | 1 | 2018 | 91 | 0.160 |
Why?
|
| Hematopoietic Cell Growth Factors | 2 | 1997 | 102 | 0.150 |
Why?
|
| Transplantation, Autologous | 6 | 2012 | 2124 | 0.150 |
Why?
|
| Heart Diseases | 1 | 2011 | 2788 | 0.150 |
Why?
|
| Blood Cell Count | 2 | 2011 | 403 | 0.150 |
Why?
|
| C-Reactive Protein | 2 | 2013 | 3778 | 0.150 |
Why?
|
| Pilot Projects | 3 | 2023 | 8324 | 0.150 |
Why?
|
| Cancer Vaccines | 1 | 2005 | 1023 | 0.150 |
Why?
|
| Stromal Cells | 1 | 2003 | 1355 | 0.150 |
Why?
|
| Cyclosporine | 2 | 2011 | 786 | 0.150 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 10 | 2018 | 11524 | 0.150 |
Why?
|
| Influenza Vaccines | 1 | 2004 | 738 | 0.150 |
Why?
|
| Aspergillus | 1 | 2016 | 85 | 0.140 |
Why?
|
| Hematopoiesis | 4 | 2018 | 2072 | 0.140 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2005 | 1270 | 0.140 |
Why?
|
| Antigens, CD34 | 1 | 2018 | 657 | 0.140 |
Why?
|
| Candida | 1 | 2016 | 172 | 0.140 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2019 | 20129 | 0.130 |
Why?
|
| Leuprolide | 1 | 1997 | 321 | 0.130 |
Why?
|
| Treatment Outcome | 22 | 2017 | 63114 | 0.130 |
Why?
|
| Antibodies, Monoclonal | 4 | 2011 | 9274 | 0.130 |
Why?
|
| Exoribonucleases | 1 | 2015 | 95 | 0.130 |
Why?
|
| Liver Failure | 1 | 1997 | 241 | 0.130 |
Why?
|
| Middle Aged | 33 | 2019 | 213383 | 0.130 |
Why?
|
| Energy Intake | 2 | 2014 | 2148 | 0.130 |
Why?
|
| Aspergillosis | 1 | 2016 | 235 | 0.130 |
Why?
|
| Epitopes | 2 | 2012 | 2571 | 0.130 |
Why?
|
| Graft Survival | 7 | 2008 | 3737 | 0.120 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2016 | 310 | 0.120 |
Why?
|
| Lung Neoplasms | 1 | 2019 | 13102 | 0.120 |
Why?
|
| Body Composition | 3 | 2013 | 2401 | 0.120 |
Why?
|
| Citrulline | 1 | 2014 | 105 | 0.120 |
Why?
|
| Heart Defects, Congenital | 1 | 2011 | 4584 | 0.120 |
Why?
|
| Candidiasis | 1 | 2016 | 366 | 0.120 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2013 | 15519 | 0.120 |
Why?
|
| Purpura, Thrombocytopenic | 1 | 1993 | 43 | 0.120 |
Why?
|
| Disease-Free Survival | 7 | 2019 | 6895 | 0.120 |
Why?
|
| Kidney Function Tests | 1 | 2016 | 684 | 0.120 |
Why?
|
| Amenorrhea | 1 | 1997 | 485 | 0.120 |
Why?
|
| Coculture Techniques | 2 | 2011 | 1341 | 0.120 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 1999 | 986 | 0.110 |
Why?
|
| 3' Untranslated Regions | 1 | 2015 | 513 | 0.110 |
Why?
|
| Tetanus Toxoid | 4 | 1998 | 193 | 0.110 |
Why?
|
| Qualitative Research | 1 | 2022 | 2682 | 0.110 |
Why?
|
| Tumor Burden | 1 | 2019 | 1915 | 0.110 |
Why?
|
| Survival Analysis | 6 | 2017 | 10252 | 0.110 |
Why?
|
| Survivors | 2 | 2014 | 2291 | 0.110 |
Why?
|
| Immunocompromised Host | 2 | 2011 | 847 | 0.110 |
Why?
|
| Antigens, CD | 5 | 1999 | 4026 | 0.110 |
Why?
|
| Pancytopenia | 1 | 1994 | 104 | 0.110 |
Why?
|
| Quality of Life | 5 | 2017 | 12804 | 0.110 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2014 | 349 | 0.110 |
Why?
|
| Erythroid Precursor Cells | 1 | 1993 | 218 | 0.110 |
Why?
|
| Inflammation Mediators | 2 | 2011 | 1889 | 0.110 |
Why?
|
| Platelet Count | 4 | 2008 | 781 | 0.100 |
Why?
|
| Obesity | 2 | 2022 | 12745 | 0.100 |
Why?
|
| Body Fluid Compartments | 1 | 2011 | 52 | 0.100 |
Why?
|
| Transplantation Chimera | 2 | 2008 | 612 | 0.100 |
Why?
|
| Watchful Waiting | 1 | 2016 | 492 | 0.100 |
Why?
|
| Membrane Proteins | 3 | 2005 | 7880 | 0.100 |
Why?
|
| Neutrophils | 2 | 2002 | 3719 | 0.100 |
Why?
|
| Erythropoiesis | 3 | 2002 | 705 | 0.100 |
Why?
|
| Mycoses | 1 | 2014 | 376 | 0.100 |
Why?
|
| Pneumococcal Vaccines | 3 | 2005 | 391 | 0.100 |
Why?
|
| Sweet Syndrome | 1 | 2011 | 47 | 0.100 |
Why?
|
| Recombinant Proteins | 5 | 2009 | 6622 | 0.100 |
Why?
|
| Anemia, Sickle Cell | 3 | 2005 | 1018 | 0.100 |
Why?
|
| Stress, Psychological | 2 | 2017 | 4245 | 0.090 |
Why?
|
| Child Welfare | 1 | 2015 | 523 | 0.090 |
Why?
|
| Prognosis | 9 | 2022 | 29063 | 0.090 |
Why?
|
| Telomerase | 1 | 2015 | 730 | 0.090 |
Why?
|
| Mouth Neoplasms | 1 | 2016 | 601 | 0.090 |
Why?
|
| Colony-Stimulating Factors | 1 | 1990 | 221 | 0.090 |
Why?
|
| Cells, Cultured | 8 | 2015 | 19229 | 0.090 |
Why?
|
| Follow-Up Studies | 8 | 2016 | 39050 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2010 | 10943 | 0.090 |
Why?
|
| Iron Chelating Agents | 1 | 2011 | 139 | 0.090 |
Why?
|
| Telomere | 1 | 2015 | 910 | 0.090 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2011 | 232 | 0.090 |
Why?
|
| Filgrastim | 1 | 2009 | 133 | 0.080 |
Why?
|
| Chemokines | 1 | 2013 | 970 | 0.080 |
Why?
|
| Registries | 3 | 2019 | 8089 | 0.080 |
Why?
|
| Waist Circumference | 1 | 2013 | 917 | 0.080 |
Why?
|
| Psychometrics | 2 | 2015 | 3002 | 0.080 |
Why?
|
| Megakaryocytes | 1 | 1993 | 545 | 0.080 |
Why?
|
| Kidney | 2 | 2023 | 7186 | 0.080 |
Why?
|
| Bilirubin | 2 | 2002 | 425 | 0.080 |
Why?
|
| Ablation Techniques | 1 | 2011 | 249 | 0.080 |
Why?
|
| Colony-Forming Units Assay | 3 | 2003 | 356 | 0.080 |
Why?
|
| Forkhead Transcription Factors | 1 | 2016 | 1613 | 0.080 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2013 | 2649 | 0.080 |
Why?
|
| Statistics, Nonparametric | 2 | 2004 | 2886 | 0.080 |
Why?
|
| Immunity, Innate | 2 | 2018 | 2958 | 0.080 |
Why?
|
| Growth Substances | 1 | 1990 | 784 | 0.080 |
Why?
|
| Glomerular Filtration Rate | 1 | 2016 | 2170 | 0.080 |
Why?
|
| Immunologic Memory | 2 | 2005 | 1348 | 0.080 |
Why?
|
| Time Factors | 15 | 2014 | 40075 | 0.080 |
Why?
|
| Immunization | 4 | 2005 | 1256 | 0.080 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2018 | 2948 | 0.080 |
Why?
|
| Etoposide | 3 | 2006 | 641 | 0.080 |
Why?
|
| Bacterial Infections | 3 | 2014 | 1401 | 0.080 |
Why?
|
| Medical Oncology | 2 | 2017 | 2265 | 0.080 |
Why?
|
| Burkitt Lymphoma | 1 | 2010 | 327 | 0.080 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2011 | 565 | 0.080 |
Why?
|
| Haemophilus influenzae | 2 | 1998 | 171 | 0.080 |
Why?
|
| Vaccines, Conjugate | 5 | 2005 | 333 | 0.080 |
Why?
|
| Antibody Formation | 3 | 2005 | 1402 | 0.080 |
Why?
|
| Antigens, CD19 | 1 | 2010 | 380 | 0.080 |
Why?
|
| Haemophilus Infections | 2 | 1998 | 95 | 0.070 |
Why?
|
| Anemia, Hemolytic | 1 | 1988 | 168 | 0.070 |
Why?
|
| Nurses | 1 | 2017 | 2461 | 0.070 |
Why?
|
| Basal Metabolism | 1 | 2008 | 168 | 0.070 |
Why?
|
| Retrospective Studies | 10 | 2022 | 77449 | 0.070 |
Why?
|
| Exercise Therapy | 1 | 2014 | 906 | 0.070 |
Why?
|
| Cohort Studies | 8 | 2016 | 40561 | 0.070 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2006 | 87 | 0.070 |
Why?
|
| Risk | 4 | 2014 | 9687 | 0.070 |
Why?
|
| Critical Illness | 1 | 2019 | 2670 | 0.070 |
Why?
|
| Infant, Newborn | 9 | 2016 | 25625 | 0.070 |
Why?
|
| Guidelines as Topic | 2 | 2005 | 1405 | 0.070 |
Why?
|
| Organ Size | 1 | 2011 | 2252 | 0.070 |
Why?
|
| Endothelium | 2 | 1988 | 778 | 0.070 |
Why?
|
| Neutropenia | 1 | 2011 | 895 | 0.070 |
Why?
|
| Blood Donors | 1 | 2008 | 355 | 0.070 |
Why?
|
| Prospective Studies | 12 | 2017 | 53288 | 0.070 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2011 | 587 | 0.070 |
Why?
|
| Palliative Care | 2 | 2017 | 3493 | 0.070 |
Why?
|
| Autoantibodies | 2 | 2005 | 2035 | 0.070 |
Why?
|
| Thalassemia | 3 | 2005 | 273 | 0.070 |
Why?
|
| Antibodies, Bacterial | 4 | 2005 | 1470 | 0.070 |
Why?
|
| Postoperative Period | 3 | 2008 | 1842 | 0.070 |
Why?
|
| Breast Neoplasms | 1 | 2013 | 20822 | 0.070 |
Why?
|
| RNA | 1 | 2015 | 2749 | 0.070 |
Why?
|
| Vitamin D Deficiency | 1 | 2015 | 1343 | 0.060 |
Why?
|
| Osteoporosis | 1 | 2015 | 1580 | 0.060 |
Why?
|
| Cytokines | 4 | 2011 | 7322 | 0.060 |
Why?
|
| Liver Function Tests | 1 | 2006 | 528 | 0.060 |
Why?
|
| Drug Evaluation | 3 | 1998 | 647 | 0.060 |
Why?
|
| Young Adult | 7 | 2022 | 56430 | 0.060 |
Why?
|
| Docosahexaenoic Acids | 1 | 2011 | 875 | 0.060 |
Why?
|
| Health Services Accessibility | 1 | 2022 | 5137 | 0.060 |
Why?
|
| Cytomegalovirus Infections | 2 | 2008 | 820 | 0.060 |
Why?
|
| Radiation Tolerance | 2 | 2018 | 486 | 0.060 |
Why?
|
| Monitoring, Immunologic | 1 | 2004 | 100 | 0.060 |
Why?
|
| Risk Factors | 8 | 2019 | 72290 | 0.060 |
Why?
|
| Salivary Glands | 1 | 2005 | 229 | 0.060 |
Why?
|
| Head and Neck Neoplasms | 1 | 2018 | 2734 | 0.060 |
Why?
|
| Laos | 1 | 2003 | 29 | 0.060 |
Why?
|
| Leukocyte Count | 3 | 2008 | 1588 | 0.060 |
Why?
|
| Immunologic Factors | 1 | 1993 | 1580 | 0.060 |
Why?
|
| Cytoplasm | 1 | 1988 | 1539 | 0.060 |
Why?
|
| Radiotherapy | 2 | 2010 | 1533 | 0.060 |
Why?
|
| Lipopolysaccharides | 1 | 2011 | 2216 | 0.060 |
Why?
|
| Skinfold Thickness | 1 | 2003 | 162 | 0.060 |
Why?
|
| Sirolimus | 1 | 2011 | 1564 | 0.060 |
Why?
|
| Carboplatin | 1 | 2006 | 801 | 0.060 |
Why?
|
| Anthropometry | 2 | 2010 | 1350 | 0.060 |
Why?
|
| Interleukin-2 | 2 | 1996 | 1904 | 0.060 |
Why?
|
| Genotype | 2 | 2017 | 12951 | 0.050 |
Why?
|
| Endothelium, Vascular | 2 | 2001 | 4456 | 0.050 |
Why?
|
| Software | 1 | 2017 | 4443 | 0.050 |
Why?
|
| Transforming Growth Factor beta | 2 | 2018 | 2007 | 0.050 |
Why?
|
| Mitochondria | 1 | 2016 | 3520 | 0.050 |
Why?
|
| Infusions, Intravenous | 2 | 2002 | 2274 | 0.050 |
Why?
|
| Adipose Tissue | 2 | 2011 | 3279 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 1 | 2011 | 6386 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2013 | 4420 | 0.050 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2008 | 1366 | 0.050 |
Why?
|
| Macrophages | 2 | 2020 | 5655 | 0.050 |
Why?
|
| Cell Extracts | 1 | 2002 | 138 | 0.050 |
Why?
|
| Animals | 10 | 2018 | 168757 | 0.050 |
Why?
|
| Costs and Cost Analysis | 2 | 2014 | 1681 | 0.050 |
Why?
|
| Bone Density | 1 | 2015 | 3468 | 0.050 |
Why?
|
| Aged | 10 | 2019 | 163280 | 0.050 |
Why?
|
| Haplotypes | 1 | 2008 | 2779 | 0.050 |
Why?
|
| Platelet Transfusion | 1 | 2005 | 314 | 0.050 |
Why?
|
| Puberty | 1 | 2005 | 490 | 0.050 |
Why?
|
| Enteral Nutrition | 1 | 2007 | 763 | 0.050 |
Why?
|
| Postnatal Care | 1 | 2003 | 236 | 0.050 |
Why?
|
| Acute Disease | 3 | 2008 | 7149 | 0.050 |
Why?
|
| Dosage Forms | 1 | 2001 | 56 | 0.050 |
Why?
|
| Drug Therapy, Combination | 2 | 2011 | 6489 | 0.050 |
Why?
|
| Evidence-Based Medicine | 2 | 2005 | 3610 | 0.050 |
Why?
|
| Killer Cells, Natural | 1 | 2009 | 2133 | 0.050 |
Why?
|
| Mitomycin | 2 | 2018 | 259 | 0.050 |
Why?
|
| Intestinal Mucosa | 1 | 2011 | 3036 | 0.050 |
Why?
|
| Bacterial Proteins | 1 | 1994 | 3848 | 0.050 |
Why?
|
| Ascites | 1 | 2002 | 344 | 0.050 |
Why?
|
| Kidney Diseases | 2 | 1988 | 2149 | 0.050 |
Why?
|
| Siblings | 2 | 2017 | 854 | 0.050 |
Why?
|
| Diagnosis, Differential | 3 | 2007 | 12959 | 0.050 |
Why?
|
| Dinoprostone | 1 | 2003 | 600 | 0.050 |
Why?
|
| Arm | 1 | 2003 | 589 | 0.050 |
Why?
|
| Serotonin Antagonists | 1 | 2000 | 144 | 0.040 |
Why?
|
| Health Care Rationing | 1 | 2003 | 437 | 0.040 |
Why?
|
| Disease Models, Animal | 1 | 2018 | 18029 | 0.040 |
Why?
|
| Ondansetron | 1 | 2000 | 90 | 0.040 |
Why?
|
| Pharmaceutical Services | 1 | 2001 | 140 | 0.040 |
Why?
|
| Lymphoma | 2 | 1999 | 1877 | 0.040 |
Why?
|
| Hodgkin Disease | 2 | 1997 | 1415 | 0.040 |
Why?
|
| Administration, Oral | 2 | 2018 | 3913 | 0.040 |
Why?
|
| Physicians | 1 | 2017 | 4567 | 0.040 |
Why?
|
| Immunoglobulin G | 4 | 2005 | 4560 | 0.040 |
Why?
|
| Autoantigens | 1 | 2003 | 892 | 0.040 |
Why?
|
| Lymphocyte Depletion | 3 | 2017 | 608 | 0.040 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2003 | 644 | 0.040 |
Why?
|
| Escherichia coli | 1 | 2011 | 4217 | 0.040 |
Why?
|
| Calorimetry, Indirect | 2 | 2010 | 183 | 0.040 |
Why?
|
| Tetanus | 1 | 1998 | 53 | 0.040 |
Why?
|
| Waiting Lists | 1 | 2003 | 692 | 0.040 |
Why?
|
| Fanconi Anemia Complementation Group G Protein | 1 | 2018 | 18 | 0.040 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2006 | 1838 | 0.040 |
Why?
|
| Demography | 2 | 2014 | 1656 | 0.040 |
Why?
|
| Fanconi Anemia Complementation Group A Protein | 1 | 2018 | 46 | 0.040 |
Why?
|
| Secondary Prevention | 1 | 2005 | 1530 | 0.040 |
Why?
|
| Mice | 6 | 2018 | 81183 | 0.040 |
Why?
|
| Muscles | 1 | 2003 | 1614 | 0.040 |
Why?
|
| Receptors, Purinergic P1 | 1 | 1998 | 109 | 0.040 |
Why?
|
| Leukemia, Lymphoid | 2 | 1988 | 315 | 0.040 |
Why?
|
| Double-Blind Method | 4 | 2015 | 12026 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2014 | 9959 | 0.040 |
Why?
|
| Genome-Wide Association Study | 1 | 2017 | 12261 | 0.040 |
Why?
|
| Recurrence | 3 | 2006 | 8340 | 0.040 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 1997 | 1381 | 0.040 |
Why?
|
| Hematopoietic Stem Cells | 4 | 2003 | 3386 | 0.040 |
Why?
|
| Ireland | 1 | 2017 | 161 | 0.040 |
Why?
|
| Genetic Complementation Test | 1 | 1998 | 562 | 0.040 |
Why?
|
| Cost Control | 1 | 2000 | 624 | 0.040 |
Why?
|
| Leukemia, Myelomonocytic, Acute | 1 | 1997 | 39 | 0.040 |
Why?
|
| Immunization Schedule | 1 | 1998 | 221 | 0.040 |
Why?
|
| Interleukin-10 | 1 | 2003 | 1200 | 0.040 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 1997 | 220 | 0.040 |
Why?
|
| Hematocrit | 1 | 1998 | 636 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 1999 | 793 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2019 | 57776 | 0.040 |
Why?
|
| Statistics as Topic | 1 | 2003 | 2373 | 0.030 |
Why?
|
| Cell Division | 2 | 2003 | 4568 | 0.030 |
Why?
|
| Remission Induction | 2 | 2006 | 2386 | 0.030 |
Why?
|
| Skin Neoplasms | 2 | 2014 | 5686 | 0.030 |
Why?
|
| Injections, Intramuscular | 1 | 1997 | 552 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2006 | 2925 | 0.030 |
Why?
|
| Feasibility Studies | 2 | 2013 | 5078 | 0.030 |
Why?
|
| Liver | 2 | 2002 | 7474 | 0.030 |
Why?
|
| Uterine Hemorrhage | 1 | 1997 | 255 | 0.030 |
Why?
|
| Biopsy | 2 | 2011 | 6756 | 0.030 |
Why?
|
| Cell Communication | 1 | 2003 | 1621 | 0.030 |
Why?
|
| Vidarabine | 1 | 2017 | 345 | 0.030 |
Why?
|
| Escherichia coli Proteins | 1 | 2002 | 1050 | 0.030 |
Why?
|
| Asthma | 1 | 2014 | 6011 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 1997 | 1420 | 0.030 |
Why?
|
| Incidence | 3 | 2014 | 20947 | 0.030 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2006 | 3523 | 0.030 |
Why?
|
| Reference Values | 1 | 2002 | 4982 | 0.030 |
Why?
|
| Prostatic Neoplasms | 1 | 2017 | 11124 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2013 | 9239 | 0.030 |
Why?
|
| Longitudinal Studies | 2 | 2015 | 13989 | 0.030 |
Why?
|
| Neovascularization, Pathologic | 1 | 2005 | 2635 | 0.030 |
Why?
|
| Fibroblasts | 3 | 2015 | 4161 | 0.030 |
Why?
|
| Linear Models | 2 | 2017 | 5952 | 0.030 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2016 | 876 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2003 | 3772 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2012 | 12720 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2004 | 2684 | 0.030 |
Why?
|
| Blotting, Western | 3 | 2011 | 5179 | 0.030 |
Why?
|
| Organs at Risk | 1 | 2016 | 346 | 0.030 |
Why?
|
| Sialoglycoproteins | 1 | 1994 | 318 | 0.030 |
Why?
|
| Receptors, Interleukin-1 | 1 | 1994 | 262 | 0.030 |
Why?
|
| Mutation | 2 | 2015 | 29786 | 0.030 |
Why?
|
| Polysaccharides, Bacterial | 1 | 1996 | 578 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1997 | 1572 | 0.030 |
Why?
|
| Emotions | 2 | 2015 | 2661 | 0.030 |
Why?
|
| Gene Transfer Techniques | 1 | 1998 | 1224 | 0.030 |
Why?
|
| Stem Cell Factor | 1 | 1993 | 219 | 0.030 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2019 | 981 | 0.030 |
Why?
|
| Organ Transplantation | 1 | 2003 | 1139 | 0.030 |
Why?
|
| Factor Analysis, Statistical | 1 | 2015 | 977 | 0.030 |
Why?
|
| Cytogenetic Analysis | 1 | 2013 | 295 | 0.030 |
Why?
|
| Endothelial Cells | 1 | 2005 | 3479 | 0.030 |
Why?
|
| Drug Administration Schedule | 2 | 1998 | 4933 | 0.030 |
Why?
|
| Bone Marrow Purging | 1 | 1991 | 109 | 0.030 |
Why?
|
| Tissue Plasminogen Activator | 1 | 1998 | 1261 | 0.030 |
Why?
|
| Stem Cells | 1 | 2005 | 3567 | 0.030 |
Why?
|
| Autoimmune Diseases | 1 | 2003 | 2133 | 0.020 |
Why?
|
| Vaccines, Synthetic | 1 | 1994 | 634 | 0.020 |
Why?
|
| Granulocytes | 1 | 1993 | 548 | 0.020 |
Why?
|
| Heparin | 1 | 1998 | 1637 | 0.020 |
Why?
|
| Umbilical Veins | 2 | 1989 | 433 | 0.020 |
Why?
|
| Sex Factors | 3 | 2015 | 10397 | 0.020 |
Why?
|
| Disease Progression | 3 | 2014 | 13284 | 0.020 |
Why?
|
| Case-Control Studies | 2 | 2005 | 21746 | 0.020 |
Why?
|
| Testicular Neoplasms | 1 | 1997 | 804 | 0.020 |
Why?
|
| Antigen Presentation | 1 | 1996 | 1284 | 0.020 |
Why?
|
| Age Factors | 4 | 2015 | 18370 | 0.020 |
Why?
|
| Cytarabine | 2 | 1990 | 692 | 0.020 |
Why?
|
| Immunoglobulin A | 1 | 1994 | 992 | 0.020 |
Why?
|
| Personal Satisfaction | 1 | 2014 | 643 | 0.020 |
Why?
|
| Ricin | 1 | 1990 | 72 | 0.020 |
Why?
|
| Nervous System Neoplasms | 1 | 1990 | 91 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2004 | 9146 | 0.020 |
Why?
|
| Immunotoxins | 1 | 1990 | 179 | 0.020 |
Why?
|
| Phytohemagglutinins | 1 | 1989 | 170 | 0.020 |
Why?
|
| Pneumococcal Infections | 2 | 2005 | 497 | 0.020 |
Why?
|
| Hepatorenal Syndrome | 1 | 2009 | 61 | 0.020 |
Why?
|
| Drug Synergism | 1 | 1993 | 1792 | 0.020 |
Why?
|
| Dendritic Cells | 1 | 2020 | 2725 | 0.020 |
Why?
|
| Immunoglobulin M | 1 | 1994 | 1537 | 0.020 |
Why?
|
| Patient Selection | 2 | 2003 | 4215 | 0.020 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 1996 | 1821 | 0.020 |
Why?
|
| Erythropoietin | 1 | 1993 | 726 | 0.020 |
Why?
|
| Lipoxins | 1 | 2011 | 412 | 0.020 |
Why?
|
| Physical Fitness | 1 | 2013 | 733 | 0.020 |
Why?
|
| Blood Urea Nitrogen | 1 | 1988 | 191 | 0.020 |
Why?
|
| United States | 4 | 2010 | 69872 | 0.020 |
Why?
|
| Red-Cell Aplasia, Pure | 1 | 1988 | 30 | 0.020 |
Why?
|
| Comorbidity | 1 | 2022 | 10388 | 0.020 |
Why?
|
| Cell Survival | 1 | 2018 | 5882 | 0.020 |
Why?
|
| Self Efficacy | 1 | 2011 | 616 | 0.020 |
Why?
|
| Pedigree | 1 | 2015 | 4644 | 0.020 |
Why?
|
| Escherichia coli Infections | 1 | 2011 | 532 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2017 | 4851 | 0.020 |
Why?
|
| Proteins | 2 | 2002 | 6103 | 0.020 |
Why?
|
| Adrenal Cortex Hormones | 1 | 1996 | 1855 | 0.020 |
Why?
|
| Cell Cycle Proteins | 1 | 1998 | 3462 | 0.020 |
Why?
|
| Culture Media | 1 | 1989 | 908 | 0.020 |
Why?
|
| Fatigue | 1 | 2014 | 1531 | 0.020 |
Why?
|
| Apoptosis | 1 | 2003 | 9727 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2010 | 13695 | 0.020 |
Why?
|
| Social Environment | 1 | 2011 | 1023 | 0.020 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 12245 | 0.020 |
Why?
|
| Self Care | 1 | 2011 | 786 | 0.020 |
Why?
|
| Hemorrhage | 1 | 1998 | 3461 | 0.020 |
Why?
|
| Graft vs Leukemia Effect | 1 | 2006 | 111 | 0.020 |
Why?
|
| Thymopoietins | 1 | 2005 | 10 | 0.020 |
Why?
|
| Absorptiometry, Photon | 1 | 2011 | 1725 | 0.020 |
Why?
|
| False Negative Reactions | 1 | 2006 | 588 | 0.020 |
Why?
|
| Carmustine | 2 | 1997 | 137 | 0.020 |
Why?
|
| Procarbazine | 1 | 1985 | 181 | 0.020 |
Why?
|
| Data Collection | 1 | 2015 | 3341 | 0.020 |
Why?
|
| Child Nutritional Physiological Phenomena | 1 | 2007 | 303 | 0.020 |
Why?
|
| Severity of Illness Index | 2 | 2016 | 15540 | 0.020 |
Why?
|
| Leukoplakia | 1 | 2004 | 18 | 0.020 |
Why?
|
| Combined Modality Therapy | 5 | 1997 | 8642 | 0.020 |
Why?
|
| Cell Adhesion Molecules | 1 | 2011 | 1602 | 0.020 |
Why?
|
| Virus Activation | 1 | 2006 | 319 | 0.020 |
Why?
|
| Leukoplakia, Oral | 1 | 2004 | 73 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2014 | 3200 | 0.020 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2015 | 1736 | 0.010 |
Why?
|
| Chromosomes, Human, Y | 1 | 2005 | 148 | 0.010 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2006 | 629 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2005 | 2505 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 3870 | 0.010 |
Why?
|
| Biological Transport | 1 | 1988 | 2118 | 0.010 |
Why?
|
| Reproducibility of Results | 2 | 2015 | 19905 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 4751 | 0.010 |
Why?
|
| Gastrointestinal Tract | 1 | 2010 | 814 | 0.010 |
Why?
|
| Dogs | 1 | 1988 | 3912 | 0.010 |
Why?
|
| Chromosomes, Human, X | 1 | 2005 | 296 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2018 | 14557 | 0.010 |
Why?
|
| Herpes Simplex | 1 | 2006 | 470 | 0.010 |
Why?
|
| RNA, Messenger | 3 | 2011 | 13033 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 1998 | 5853 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2014 | 6538 | 0.010 |
Why?
|
| Leukocytes | 1 | 2011 | 2043 | 0.010 |
Why?
|
| HLA-A2 Antigen | 1 | 2003 | 213 | 0.010 |
Why?
|
| Hepatitis, Viral, Human | 1 | 2003 | 138 | 0.010 |
Why?
|
| Tongue Neoplasms | 1 | 2004 | 180 | 0.010 |
Why?
|
| Simplexvirus | 1 | 2006 | 802 | 0.010 |
Why?
|
| Phosphoproteins | 1 | 2011 | 2440 | 0.010 |
Why?
|
| Cytomegalovirus | 1 | 2006 | 732 | 0.010 |
Why?
|
| Dietary Carbohydrates | 1 | 2007 | 906 | 0.010 |
Why?
|
| Logistic Models | 1 | 2017 | 13408 | 0.010 |
Why?
|
| Dietary Proteins | 1 | 2007 | 963 | 0.010 |
Why?
|
| Multicenter Studies as Topic | 1 | 2006 | 1677 | 0.010 |
Why?
|
| Pregnancy | 1 | 2003 | 29144 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 1996 | 12354 | 0.010 |
Why?
|
| Gastrointestinal Diseases | 1 | 2010 | 1170 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 2003 | 1095 | 0.010 |
Why?
|
| Nutritional Status | 1 | 2010 | 1609 | 0.010 |
Why?
|
| Vitamin D | 1 | 2015 | 3223 | 0.010 |
Why?
|
| Anemia, Diamond-Blackfan | 1 | 2002 | 137 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 1998 | 9648 | 0.010 |
Why?
|
| Gene Library | 1 | 2003 | 1074 | 0.010 |
Why?
|
| Japan | 1 | 2005 | 1360 | 0.010 |
Why?
|
| Fetal Blood | 1 | 2006 | 1318 | 0.010 |
Why?
|
| Blood Vessels | 1 | 1986 | 1125 | 0.010 |
Why?
|
| Caregivers | 1 | 2011 | 2094 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2003 | 2050 | 0.010 |
Why?
|
| Molecular Targeted Therapy | 1 | 2011 | 2727 | 0.010 |
Why?
|
| Ribosomal Proteins | 1 | 2002 | 360 | 0.010 |
Why?
|
| Phenotype | 1 | 2017 | 16365 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2016 | 16689 | 0.010 |
Why?
|
| Dietary Fats | 1 | 2007 | 2017 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2011 | 3690 | 0.010 |
Why?
|
| Fanconi Anemia Complementation Group Proteins | 1 | 1998 | 100 | 0.010 |
Why?
|
| Models, Biological | 1 | 1994 | 9583 | 0.010 |
Why?
|
| Immune Sera | 1 | 1998 | 641 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2014 | 7913 | 0.010 |
Why?
|
| Glycoproteins | 1 | 1986 | 2263 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2016 | 21827 | 0.010 |
Why?
|
| Cell Lineage | 1 | 2006 | 2504 | 0.010 |
Why?
|
| Skin | 1 | 2011 | 4364 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 1986 | 3206 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 1998 | 898 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 2 | 1990 | 1681 | 0.010 |
Why?
|
| Retroviridae | 1 | 1998 | 914 | 0.010 |
Why?
|
| Antibodies, Viral | 1 | 2006 | 3176 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2011 | 10481 | 0.010 |
Why?
|
| Bacterial Capsules | 1 | 1996 | 251 | 0.010 |
Why?
|
| Aging | 1 | 1994 | 8664 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2018 | 23403 | 0.010 |
Why?
|
| Liver Diseases | 1 | 2003 | 1253 | 0.010 |
Why?
|
| Cell Line | 1 | 1988 | 15997 | 0.010 |
Why?
|
| Bacterial Vaccines | 1 | 1996 | 403 | 0.010 |
Why?
|
| Length of Stay | 1 | 2007 | 6309 | 0.010 |
Why?
|
| Research Design | 1 | 2010 | 5987 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2011 | 11483 | 0.010 |
Why?
|
| Mortality | 1 | 2005 | 2864 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2011 | 7181 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 14722 | 0.010 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 1994 | 297 | 0.010 |
Why?
|
| Interleukin-4 | 1 | 1996 | 1147 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2008 | 15076 | 0.010 |
Why?
|
| Leukemia, Radiation-Induced | 1 | 1990 | 40 | 0.010 |
Why?
|
| Methotrexate | 1 | 1997 | 1727 | 0.010 |
Why?
|
| Actuarial Analysis | 1 | 1990 | 378 | 0.010 |
Why?
|
| Cell Cycle | 1 | 1998 | 2967 | 0.010 |
Why?
|
| Pain | 1 | 2005 | 4986 | 0.010 |
Why?
|
| Drug Resistance | 1 | 1994 | 1609 | 0.000 |
Why?
|
| Primary Myelofibrosis | 1 | 1990 | 215 | 0.000 |
Why?
|
| Tissue and Organ Procurement | 1 | 1996 | 896 | 0.000 |
Why?
|
| Base Sequence | 1 | 1998 | 12797 | 0.000 |
Why?
|
| Wiskott-Aldrich Syndrome | 1 | 1986 | 131 | 0.000 |
Why?
|
| Amino Acid Sequence | 1 | 1998 | 13815 | 0.000 |
Why?
|
| DNA, Recombinant | 1 | 1986 | 476 | 0.000 |
Why?
|
| Neprilysin | 1 | 1988 | 439 | 0.000 |
Why?
|
| Molecular Sequence Data | 1 | 1998 | 18111 | 0.000 |
Why?
|
| Gene Expression Regulation | 1 | 2003 | 12072 | 0.000 |
Why?
|
| Postoperative Complications | 1 | 2006 | 15295 | 0.000 |
Why?
|
| Surface Properties | 1 | 1986 | 1184 | 0.000 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 1986 | 547 | 0.000 |
Why?
|
| Heart Failure | 1 | 1986 | 10900 | 0.000 |
Why?
|
| Fibronectins | 1 | 1986 | 726 | 0.000 |
Why?
|
| Cell Count | 1 | 1986 | 1856 | 0.000 |
Why?
|
| Staining and Labeling | 1 | 1986 | 1100 | 0.000 |
Why?
|
| Cytoskeleton | 1 | 1986 | 1185 | 0.000 |
Why?
|
| Antigens, Neoplasm | 1 | 1988 | 1988 | 0.000 |
Why?
|
| Preoperative Care | 1 | 1988 | 2250 | 0.000 |
Why?
|
| Actins | 1 | 1986 | 2121 | 0.000 |
Why?
|
| Multiple Myeloma | 1 | 1994 | 5181 | 0.000 |
Why?
|
| Body Weight | 1 | 1986 | 4669 | 0.000 |
Why?
|